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Abstract The use of FEV1/FEV6 in place of the traditional FEV1/FVCto detect airways obstruction during spirometry
testingperformedbyprimarycare providerswouldreduce time andpatienteffort.Wehypothesized thatthe FEV1/FEV6,
would predict the subsequent decline in FEV1 in adult cigarette smokers who enrolled in the multicenter Lung Health
Study.Ten clinical centers in the U.S. and Canada recruited 5887 male and female smokers, aged 35--60 years, with bor-
derlinetomild airwaysobstructionbyspirometry.Thosewho successfully stopped smokingduring the 5-yr study (usually
as the result of the smoking cessation intervention) were excluded from this analysis. In those continuing to smoke, the
relative strength of spirometric predictors of the change in FEV1 during 5 years of follow-up (DFEV1) was determined
using a linear regressionmodel.The following covariateswere significant independent predictors of DFEV1: the baseline
degree of airways obstruction, age, gender, cigarettes per day, years of education, and bronchial hyperresponsiveness.
The FEV1/FEV6 was nearly as strong an independent predictor as was the FEV1/FVC (a traditional index of airways
obstruction).The degree of airways obstruction, as determined by the FEV1/FEV6 from spirometry, is an independent
predictor of subsequent decline in lung function; and therefore, may be used to detect smokers at higher risk of
developing COPD.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1270, available online athttp://www.idealibrary.comon
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The availability of easy-to-use lung function tests would
help in developing the case for more widespread lung
function testing in both primary care and sub-specialty
settings. Barriers to the more widespread use of o⁄ce
spirometry include the expense of the equipment, the
di⁄culty of administering and performing the test, and
the perception that there is inadequate evidence that
doing the test a¡ects patient outcomes.
Ample information presently exists that spirometry
results detect the adult cigarette smokers who are likely
to develop clinically signi¢cant COPD.The FEV1is also an
excellent predictor of morbidity andmortality (1,2).Due
to this large evidence base, the National Lung Health
Education Program recommends that primary care pro-
viders (PCPs) use o⁄ce spirometry to detect airways
obstruction in all adult cigarette smokers seen in their
outpatientclinics, and then to use the results topromote
smoking cessation (3).
Many patients have di⁄culty exhaling until current
‘end-of-test’ standards for accurately measuring FVCCorrespondence should be addressed to:Dr. Paul Enright,The
University of Arizona,1501NCampbell Ave, Rm 2342,Tucson, AZ
85724.Fax: +1520 626 6970; E-mail: lungguy@aol.comaremet (4). Shortening each forced exhalationmaneuver
to 6 sec (resulting in the FEV6)wouldreducebothpatient
and technician e¡ort and fatigue, and testing time, possi-
bly making spirometry more appealing to both primary
care and subspecialty providers. A shorter maneuver
durationwould alsomake it easier for o⁄ce spirometers
to accurately measure low £ows at the end of the man-
euvers, making o⁄ce spirometers less expensive.
In the subgroup of continuing smokers in themulticen-
ter LungHealth Study (LHS), severalvariableswere inde-
pendent predictors of the subsequent fall in FEV1 over
the 5-yr follow-up, including FEV1/FVC, age, cigarettes
smoked per day, bronchodilator response, and metha-
choline responsiveness (5). These results provided addi-
tional evidence that the FEV1/FVC predicts decline in
lung function in adult smokers, and therefore, may be
used to de¢ne‘early COPD’.
Predicted reference values and lower limits of the
normal range for the FEV6 and the FEV1/FEV6 from a
large population-based sample were recently published
(6).The FEV1/FEV6 was found to be an accurate and reli-
able alternative for the FEV1/FVC for diagnosing airways
obstruction in a large group of patients referred to a
pulmonary function laboratory (7). The purpose of this
analysis of LHS data is to provide further evidence
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tional FEV1/FVC when detecting early COPD in adult
cigarette smokers.
METHODS
Design and recruitment
The Lung Health Study was a randomized multicenter
clinical trial, carried out from October 1986 to April
1994, designed to test the e¡ectiveness of interven-
tionFsmoking cessation andbronchodilator administra-
tionFin smokers thought to be in the early stages of
COPD. Detailed descriptions of the design and recruit-
ment have been published (8,9). Entry criteria were
chosen to identify otherwise healthy current smokers,
aged 35^65 years, who had airways obstruction and
who did not have conditions that would compromise
follow-up or interpretation of lung function.For the pur-
pose of study eligibility, airways obstructionwas de¢ned
as an FEV1/FVC of 70% or less and an FEV1 between 55
and 90% of predicted.Candidates for the study were ex-
cluded if they reported factors thatmight interferewith
follow-up (such as more than 25 alcoholic drinks per
week), or if they regularly used physician-prescribed
bronchodilators, beta-blockers, nitrates for angina, cor-
ticosteroids, or insulin.The studydesignwas approvedby
the Human Studies Review Boards of each participating
institution, and informed consent was obtained from all
study participants.
Volunteers for the study were recruited in a variety
of ways, including media publicity, mass mailings, and
worksite andpublic screening.Exclusionarycriteria were
examined at the second screening visit.Current smokers
who quali¢ed then attended a third screening (S3) visit at
which time a detailed history of respiratory symptoms,
pre-existing diseases, smoking status was asked (and
veri¢ed by salivary cotinine and exhaled carbon monox-
ide levels), and spirometry and methacholine challenge
tests were performed (10,11). Participants were then
randomized to one of three study groups: SIA, special
intervention with an intensive smoking cessation
program, plus a prescription for an ipratropiumbromide
inhaler to be taken four times per day; SIP, special inter-
vention with an intensive smoking cessation program,
and a placebo inhaler; or UC, no cessation program and
no inhaledmedication (usual care).
Interventions
The smoking cessation program was the same for all 10
clinical centers as previously described in detail (12). At
the time of randomization, all SIA and SIP participants
were interviewed by a physician who strongly recom-
mended that they stop smoking, explaining in detail that
they were at very high risk for symptomatic COPD.Group smoking cessation sessions met 12 times in 10
weeks with an early quit day, behavior modi¢cation
techniques, and aggressive replacement therapy using
nicotine gum, provided at no cost (13). Those who quit
entered a maintenance program aimed at preventing
relapse. The SIA group were prescribed daily inhaled
ipratropium bromide while the SIP group were given
placebo inhalers.
Spirometry testing
Details of the pre and post-bronchodilator spirometry
procedures have previously been published (10). A
methacholine challenge test (MCT) was performed
about 3 weeks after the baseline spirometry testing (11).
During ¢ve annual follow-up examinations, spirometry
was repeated and smoking status determined (self-
reported and biochemically validated) (12).
Analyses
Only the subset of LHS participants who continued to
smoke cigarettes during the 5-yr follow-up were ana-
lyzed for this report. The baseline to 5-yr follow-up
change in FEV1 (DFEV1, in mlyr
1) was the dependent
variable in linear regression models. We determined
which of several measures of baseline airways obstruc-
tion best predicted subsequent FEV1 decline, when
correcting for age, gender, cigarettes per day, years of
education, treatment group, BD response, and MCT
slope. Candidate obstruction variables included raw
FEV1, %predicted FEV1, FEV1/FVC, and FEV1/FEV6 (26). It
was determined a priori that the R2 of eachmodelwould
be the criterion for comparing the ¢ve models. SAS
version 6 (Cary,NC) was used for statistical analyses.
RESULTS
Selected baseline characteristics of the 1767 men and
1060 women who were classi¢ed as continuing smokers
are shown in Table 1. Male and female participants had
similar average values for FEV1 percent of predicted
(75%), FEV1/FEV3 (76%), FEV1/FEV6 (69%), and FEV1/FVC
(63%).Men had signi¢cantly larger mean values for most
of the other baselinevariables inTable1, including the re-
ported number of cigarettes smoked per day, pack-years
of smoking, years of education, body mass index (BMI),
and the absolute pulmonary function measures FEV1,
FEV3, FEV6, and FVC.Women were more likely to react
to methacholine, while men had a slightly lower (and
non-signi¢cant) mean percent response to the broncho-
dilator. Ninety four percent of the participants per-
formed spirometry testing at the ¢fth year of follow-up.
The spirometry variables were highly correlated.The
correlation coe⁄cients were FVCvs. FEV1 = 0?902; FVC
TABLE 1. Baselinecharacteristicsof LungHealth Studyparticipantswhowereclassi¢edascontinuingsmokersthrough 5 yrsof
follow-up
Men (n=1767) Women (n=1060)
BaselineVariable Mean SD SE Mean SD SE
Age, years 48?1 6?9 0?2 48?1 6?6 0?2
BMI, kgm2 26?1 3?7 0?1 24?1 3?9 0?1
Education, years 13?6 2?9 0?1 13?0 2?5 0?1
Cigarettes day1 33?2 13?2 0?3 29?9 12?0 0?4
Pack-yrs 42?7 19?7 0?5 36?0 16?6 0?5
FEV1, liters 2?95 0?48 0?01 2?09 0?36 0?01
FEV3, liters 3?91 0?61 0?01 2?74 0?45 0?01
FEV6, liters 4?31 0?65 0?02 3?02 0?48 0?01
FVC, liters 4?72 0?70 0?02 3?30 0?50 0?02
FEV1/FEV3, % 75?6 4?3 0?1 76?5 3?9 0?1
FEV1/FEV6, % 68?5 5?2 0?1 69?3 4?8 0?1
FEV1/ FVC, % 62?7 6?1 0?1 63?5 5?6 0?2
FEV1% predicted 74?8 9?5 0?2 74?9 9?3 0?3
BDresponse, % 4?03 4?93 0?12 4?25 5?30 0?16
PC-20r10mgml1, %ppts 45?1 49?8 1?1 73?6 44?1 1?4
MCTslope 8?60 17?3 0?4 16?7 26?1 0?8
Mean annual DFEV1, mlyr
1 60?6 54?0 1?3 52?9 39?6 1?2
ppts; studyparticipants; SD: standard deviation; SE: standard error;MCTslope: the degree of bronchial responsiveness from
the baselinemethacholine challenge test.
FIG. 1. The mean di¡erence between two indices of airway
obstruction, the new FEV1/FEV6 and the traditional FEV1/FVC,
as a function of the degree of airways obstruction, in deciles of
FEV1/FVC on the horizontal axis, for men and for women.The
vertical bars approximate +/2 standard errors. The two in-
dices are highly correlated, but the FEV1/FEV6 is higher than the
FEV1/FVC (by 6^9%) insmokerswithmoderate airwaysobstruc-
tion (a ratio of 50^60%).&:Men;*:Women.
TABLE 2. Ratesofdeclinein FEV1 (mlper yr) bydecilesof
FEV1/FEV6, strati¢ed bygender
Men (n=1767) Women (n=1060)
FEV1/FEV6 Mean (SD) Mean (SD)
Lowestdecile 93?2 (71?5) 78?2 (47?0)
2nd decile 74?3 (57?1) 68?3 (47?4)
3rd decile 65?0 (55?7) 60?0 (43?3)
4th decile 66?1 (57?5) 51?6 (38?0)
5th decile 57?8 (48?6) 56?6 (40?1)
6th decile 51?2 (48?6) 41?3 (31?9)
7th decile 48?1 (44?2) 50?5 (31?9)
8th decile 54?9 (43?6) 44?1 (32?1)
9th decile 50?9 (44?9) 40?8 (30?0)
Highestdecile 44?5 (45?4) 37?7 (30?7)
Participants with the lowest decile of FEV1/FEV6 had
the most severe degree of baseline airways obstruction,
andthelargest subsequentmeandeclinesin lung function
(indicating faster progression of COPD).
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the FEV6 was112ml smaller than the FVC.Figure1 com-
pares the new index of airways obstructionFthe FEV1/
FEV6Fwith the traditional FEV1/FVC over the range of
severity of airways obstruction.The di¡erence between
these two variables was 6^9% larger in those smokers
withmore severe airways obstruction.Themean declines in FEV1among continuing smokers
were 61mlyr1 in men and 53mlyr1 in women.Table 2
shows the bivariate association of the degree of baseline
airway obstruction (as measured by the FEV1/FEV6, in
deciles) and the subsequent mean rates of decline in
FEV1 in men and women. Those with the most severe
TABLE 4. Comparison of the strength (linear model
R2x100%) of various baseline (S3 visit) spirometric mea-
sures of airways obstruction in predicting mean change
in FEV1in continuing smokers.Themodel includes age, ci-
garettes smokedperday, educationlevel, study treatment
group,BDresponse, andmethacholine responsiveness
Men Women
FEV1%pred 6?9 8?6
FEV1/FEV6 10?7 14?0
FEV1/FVC 11?4 14?0
FEV1/FEV6 PREDICTSLUNGFUNCTIONDECLINE INADULTSMOKERS 447degree of airways obstruction at the baseline exam (the
lowest decile of FEV1/FEV6) lost more than twice as
much lung function over the next 5 yrs when compared
to those with the least baseline airways obstruction
(for instance, FEV1 fell 93?2mlyr
1 vs. 44?5mlyr1 for
men).
Table 3 shows the results of the linear regression ana-
lysis used to determine the independent predictors of
the annual change in FEV1frombaseline toYear 5, for con-
tinuing smokers. A negative coe⁄cient for a given vari-
able implies that an increase in that variable is associated
with a faster rate of decline in FEV1.Thus, since age has
coe⁄cient of minus 0?47, an increase of 10 yrs in age
predicts 4?7mlyr1 additional loss of FEV1. Men had
faster rates of decline than women (probably an e¡ect
of larger body size). Most of the baseline variables en-
tered in this analysiswere signi¢cantpredictors of subse-
quent changes in FEV1. Higher baseline values for age,
baseline cigarettes per day, bronchodilator response,
and greater methacholine reactivity were associated
with larger rates of decline in FEV1, while being in treat-
ment group SIA (vs. UC) and having a higher baseline
FEV1/FEV6 % were associated with slower rates of FEV1
decline.
The overall R2 for the regression model that included
FEV1/FEV6was11?3%.Thismeans that themodelpredicts
about 11% of the variance in subsequent change in lung
function.Unmeasured factors (perhaps genetic) account
for most of the variation in lung function decline.Table 4
indicates the R2 values for regressionmodels done sepa-
rately in men and women, in which one of the following
baseline spirometry variables was entered: FEV1 %pre-
dicted, FEV1/FEV6, or FEV1/FVC. The ‘best’ models, in
the sense of having the largest R2, were those which in-
cluded FEV1/FVC, but the di¡erence in R
2 between these
models and those in which FEV1/FEV6 was entered was
not signi¢cant. On the other hand, FEV1 percent pre-
dicted was clearly a signi¢cantly weaker predictor of
subsequent decline in FEV1.TABLE 3. Linear regressionmodelpredictingmean change in F
Predictor Estimate
Gender (men vs. women) 6?71
Age 0?47
Cigarettes day1 (baseline) 0?33
BDresponse % 0?95
MCTslope 0?23
FEV1/FEV6% (baseline) 2?24
Education (yrs) 0?05
Treatmentgroup (SIA vs.UC) 6?60
Treatmentgroup (SIP vs.UC) 0?12
R2:11?3%; n:1767 men and1060 women;NS: not signi¢cant (PDISCUSSION
Our results con¢rm the ‘horse-racing e¡ect’ ¢rst
described by Fletcher et al. (14): the baseline degree of
airways obstruction is a predictor of the subsequent
worsening in airways obstruction (decline of FEV1) in
adult cigarette smokers. Burrows et al. found that one
can reasonably predict a relatively rapid decline in lung
function by ¢nding low lung function (a low FEV1/FVC)
in male (but not female) current cigarette smokers (15).
The analogy is that if you glance at horses midway
through a race, those horses which are ahead probably
got there by running faster during the ¢rst half of the
race, and they aremore likely to ¢nish ahead of the other
horses. Burrows concluded that ‘there appears to be
overwhelming evidence supporting the value of early
detection of obstructive airways disease to allow the
institution of vigorous antismoking e¡orts among those
with early airway obstruction.’
Our results also con¢rm those of Fletcher’s and
extend them to include female smokers. Burrows’ study
included141male and152 female smokers, with amean of
5?4 FEV1measurements over10 yrs (15), whilewe studied
approximately 10 times as many continuing male and
female smokers with six FEV1measurements over 5 yrs,
giving us considerablymore power to detect an e¡ect inEV1 (mlyr
1) in continuing smokers over 5 yrs of follow-up
TStatistic P value SE
3?58 0?0003 1?87
3?64 0?0003 0?13
4?72 0?0001 0?07
5?32 0?0001 0?18
5?32 0?0001 0?04
12?52 0?0001 0?18
0?15 NS 0?32
3?12 0?0018 2?12
0?06 NS 2?12
40?05)
448 RESPIRATORYMEDICINEwomen as well as in men. Both studies excluded those
with very low baseline FEV1 and those with known
asthma. Burrows’ study also found that the FEV1/FVC
ratio was the best spirometric predictor of subsequent
change in FEV1.
Airways obstruction in smokers, in addition to pre-
dicting subsequent rapid decline in lung function, was
also a strong independent predictor of morbidity and
mortality from cardiovascular disease and COPD (and
all-cause mortality) in several large longitudinal studies
(1,2,16^18). Based on such evidence, one group of investi-
gators suggested over 10 yrs ago that ‘perhaps it is time
that this test (spirometry) was more generally applied’
(17).
Many factors are associated with an increase in the
risk of a cigarette smoker developing COPD (objectively
measured as reduced lung function). These include her-
edity and genetic factors (19), childhood respiratory in-
fections (20), the age of onset, intensity, and duration of
smoking (21), environmental particulate exposures (22),
and the presence of airway hyper-responsiveness (11). It
is di⁄cult to accurately measure all of these factors in a
given patient. The smoking history is subject to recall
bias. Occupational and environmental exposures are
rarely measured for a single patient, and methacholine
challenge testing is time consuming and oftenunavailable
in smaller communities. Measurement of spirometry, on
the other hand, is relatively quick and easy to perform in
the outpatient setting, and an objective predictor of the
patient developing COPD.
Currently available diagnostic spirometersusually cost
more than (U.S.) $2000, inhibiting their widespread pur-
chase by primary care physicians (PCPs).One of the fac-
tors keeping the cost high is the need for relatively
expensive £ow sensors to measure the very low £ows
that occur towards the end of FVC maneuvers. Forced
expiratory maneuvers in patients with airway obstruc-
tion often last for 10^20 sec before a plateau is reached
(23) in order to meet current ATS spirometry speci¢ca-
tions for an acceptable end-of-test (25). This makes the
spirometry test session more di⁄cult for the patient
and the technician, and more time-consuming, further
inhibiting its widespread use by PCPs for detecting
COPD in adult smokers. Shorter duration maneuvers
make spirometry easier and faster. The use of the FEV6
instead of the FVC for the detection of air£ow limitation
allows all the maneuvers to be shortened to only 6 sec.
This study demonstrates that the use of the FEV1/FEV6
is a good substitute for the FEV1/FVC when screening
smokers for the presence of airways obstruction and
predicting an abnormal rate of decline in lung function
(whichwould eventually become clinical COPD).
In order to use the FEV1/FEV6 ratio to detect airways
obstruction in middle-aged smokers, and minimize the
false positive and false negative rates, the results from a
given patient must be compared to an age, gender, andrace adjustedpredictedvalue (and lower limit of the nor-
mal range) for the FEV1/FEV6 (25). Studies providing
spirometry reference equations which are currently
used in North America have not published predicted
values for the FEV1/FEV6. However, recently published
spirometry reference equations from the third National
Health andNutrition Examination Survey (NHANES III),
a sample of the general United States population, in-
cludes FEV1/FEV6 reference equations for both men and
women aged 8^80, and three major race/ethnic groups
(6). The lower limit of the normal range for the FEV1/
FEV6 for 40^60-year-old smokers is about 73% (range
70^76%). The exact value depends on age, gender, and
race. When spirometer manufacturers change the
prediction equations and automated interpretations to
utilize the FEV1/FEV6, most clinicians will probably not
notice because these internal functions are like a ‘black
box’.
Characteristics of our studymay a¡ect generalization
of our results to all patients seen in the outpatient prac-
tices of PCPs.Weused spirometry technicianswhowere
highly trained and motivated to obtain maximal and
reproducible results, whichmay not be the case in some
primary care settings.Weused very accurate diagnostic-
quality volume-sensing spirometers with customized
automated maneuver quality checks, and £ow^volume
curveswere superimposed on a large computermonitor.
These features may not be available in lower cost o⁄ce
spirometers. Our cohort consisted largely of middle-
class, middle-aged Caucasian smokers, in contrast to
the majority of patients seen in many inner-city clinics.
Nevertheless, manufacturers are developing relatively
low cost, yet accurate o⁄ce spirometers, with auto-
mated quality checks, which incorporate the new FEV1/
FEV6 reference equations.Thesenewinstruments should
then allow primary care providers to easily detect mild
airways obstruction in cigarette smokers, with accepta-
ble positive and negative predictive power, in order to
determine their risk of developing COPD.
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